Skip to main content
. 2016 Aug 11;18(10):1434–1441. doi: 10.1093/neuonc/now091

Table 1.

Confirmed and potential pseudoprogression

Patients, n (%)
BEV + RT/TMZ
(n = 458)
Plb + RT/TMZ
(n = 463)
End of treatment break
 Potential pseudoprogression 12 (2.6) 84 (18.1)
End of second maintenance cycle
 Confirmed pseudoprogression 10 (2.2) 43 (9.3)
 Confirmed progression 1 (0.2) 35 (7.6)
 Missing 1 (0.2) 6 (1.3)

Abbreviations: BEV, bevacizumab; Plb, placebo.